| Literature DB >> 26786282 |
Tingting Chai1,2, Feng Cui2, Pengqian Mu1, Yang Yang2, Nana Xu1, Zhiqiang Yin1, Qi Jia1, Shuming Yang1, Jing Qiu1, Chengju Wang2.
Abstract
Enantioselective enrichment of chiral PCB149 (2,2',3,4',5',6-hexachlorobiphenyl) was analysed in adult zebrafish (Danio rerio) exposed to the racemate, (-)-PCB149, and (+)-PCB149. Greater enrichment of (-)-PCB149 compared to (+) PCB149 was observed following 0.5 ng/L exposure; however, as the exposure time and concentration increased, racemic enrichment was observed in adult fish exposed to the racemate. No biotransformation between the two isomers was observed in fish exposed to single enantiomers. When zebrafish were exposed to different forms of chiral PCB149, enantioselective expression of genes associated with polychlorinated biphenyls (PCBs) was observed in brain and liver tissues and enantioselective correlations between bioconcentration and target gene expression levels were observed in brain and liver tissues. The strong positive correlations between expression levels of target genes (alox5a and alox12) and PCB149 bioconcentration suggest that prolonged exposure to the racemate of chiral PCB149 may result in inflammation-associated diseases. Prolonged exposure to (-)-PCB149 may also affect metabolic pathways such as dehydrogenation and methylation in the brain tissues of adult zebrafish. Hepatic expression levels of genes related to the antioxidant system were significantly negatively correlated with bioconcentration following exposure to (+)-PCB149.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26786282 PMCID: PMC4726444 DOI: 10.1038/srep19478
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
The detected PCB149 concentrations in collected water samples.
| Test period | Theoretical concentration | Actual concentration | ||
|---|---|---|---|---|
| (−)-PCB149 exposure | (+)-PCB149 exposure | |||
| 0 dpe | control | – | – | – |
| 0.5 ng/L | 0.55 ± 0.05 ng/L | 0.53 ± 0.03 ng/L | 0.49 ± 0.07 ng/L | |
| 0.1 μg/L | 0.11 ± 0.01 μg/L | 0.10 ± 0.00 μg/L | 0.09 ± 0.00 μg/L | |
| 0.25 μg/L | 0.27 ± 0.04 μg/L | 0.25 ± 0.01 μg/L | 0.23 ± 0.05 μg/L | |
| 1 dpe | control | – | – | – |
| 0.5 ng/L | 0.45 ± 0.03 ng/L | 0.43 ± 0.02 ng/L | 0.40 ± 0.06 ng/L | |
| 0.1 μg/L | 0.11 ± 0.00 μg/L | 0.09 ± 0.01 μg/L | 0.10 ± 0.01 μg/L | |
| 0.25 μg/L | 0.22 ± 0.02 μg/L | 0.24 ± 0.00 μg/L | 0.21 ± 0.03 μg/L | |
| 7 dpe | control | – | – | – |
| 0.5 ng/L | 0.52 ± 0.04 ng/L | 0.45 ± 0.04 ng/L | 0.51 ± 0.05 ng/L | |
| 0.1 μg/L | 0.10 ± 0.01 μg/L | 0.10 ± 0.00 μg/L | 0.11 ± 0.01 μg/L | |
| 0.25 μg/L | 0.26 ± 0.01 μg/L | 0.27 ± 0.00 μg/L | 0.24 ± 0.00 μg/L | |
| 14 dpe | control | – | – | – |
| 0.5 ng/L | 0.49 ± 0.01 ng/L | 0.55 ± 0.02 ng/L | 0.52 ± 0.06 ng/L | |
| 0.1 μg/L | 0.12 ± 0.00 μg/L | 0.10 ± 0.00 μg/L | 0.09 ± 0.01 μg/L | |
| 0.25 μg/L | 0.22 ± 0.04 μg/L | 0.27 ± 0.01 μg/L | 0.24 ± 0.03 μg/L | |
| 28 dpe | control | – | – | – |
| 0.5 ng/L | 0.51 ± 0.07 ng/L | 0.48 ± 0.05 ng/L | 0.53 ± 0.04 ng/L | |
| 0.1 μg/L | 0.11 ± 0.00 μg/L | 0.10 ± 0.01 μg/L | 0.11 ± 0.00 μg/L | |
| 0.25 μg/L | 0.26 ± 0.00 μg/L | 0.27 ± 0.01 μg/L | 0.23 ± 0.02 μg/L | |
aThis concentration is the total contamination of two isomers.
Figure 1Concentrations of (−)-PCB149 and (+)-PCB149 and EF values following exposure to racemate.
(A) adult zebrafish exposed to 0.5 ng/L; (B) adult zebrafish exposed to 0.1 μg/L; (C) adult zebrafish exposed to 0.25 μg/L. Asterisks denote significant differences between treatments and control (determined by Dunnett post hoc comparison, P < 0.01, **). Error bars indicate standard deviations.
Concentrations of (−)-PCB149/(+)-PCB149 in adult zebrafish when exposed to enantiomers.
Figure 2The effect of the duration and concentration of racemic-, (−)-, and (+)-PCB149 on hepatic expression levels of indicated genes relative to the no-addition control.
(A) transcription of genes involved in antioxidant system; (B) transcription of genes involved in lipid-peroxidation; (C) transcription of genes involved in dehydrogenation; (D) transcription of genes involved in methylation; E: transcription of CYP450; (a) transcription of Gpx genes at 0.25 μg/L with time.
Figure 3The effect of the duration and concentration of racemic-, (−)-, and (+)-PCB149 on cerebral expression levels of indicated genes relative to the no-addition control.
(A) transcription of genes involved in antioxidant system; (B) transcription of genes involved in lipid-peroxidation; (C) transcription of genes involved in dehydrogenation; (D) transcription of genes involved in methylation; (E) transcription of CYP450; (a) transcription of Gpx genes after 14 days of exposure at different concentrations.
Correlation coefficients between bioconcentration and expression levels of all target genes.
| Gene | Correlation coefficient | |||||
|---|---|---|---|---|---|---|
| Brain | Liver | |||||
| Racemate | (−)-PCB149 | (+)-PCB149 | Racemate | (−)-PCB149 | (+)-PCB149 | |
| 0.057 | −0.331 | −0.675 | −0.351 | −0.095 | −0.331 | |
| −0.141 | −0.496 | −0.032 | −0.336 | 0.002 | −0.520** | |
| 0.080 | −0.323 | −0.289 | −0.187 | −0.122 | −0.522 | |
| 0.378 | −0.394 | 0.088 | −0.217 | −0.042 | −0.454 | |
| −0.05 | −0.435 | −0.113 | 0.161 | 0.140 | −0.087 | |
| 0.119 | −0.112 | 0.125 | −0.270 | −0.176 | −0.321 | |
| −0.231 | −0.319 | −0.016 | 0.004 | −0.087 | −0.330 | |
| 0.543 | −0.002 | −0.147 | −0.038 | 0.152 | −0.513 | |
| 0.394 | 0.082 | −0.1 | −0.210 | 0.016 | −0.178 | |
| −0.021 | −0.500 | −0.05 | −0.351 | −0.041 | −0.362 | |
| 0.040 | −0.574 | −0.153 | −0.266 | −0.028 | −0.174 | |
| −0.313 | −0.217 | −0.736 | −0.340 | −0.036 | −0.239 | |
| 0.639 | −0.006 | −0.267 | −0.226 | 0.070 | −0.502 | |
| −0.238 | −0.437 | 0.210 | −0.019 | 0.013 | −0.322 | |
*P < 0.05 according to Spearman’s test;
**P < 0.01 according to Spearman’s test.
Figure 4Loading diagram for PCA analysis of PCB149 concentrations and relative transcriptional level of indicated genes after exposure to:
(A,D) racemate; (B,E) (−)-PCB149; (C,F) (+)-PCB149; (A–C) in brain; (D–F) in liver. Green diamond marks represent samples and blue triangle marks represent genes. *P < 0.05 according to Spearman’s test; **P < 0.01 according to Spearman’s test.
Sequences of primer pairs used for real-time quantitative PCR.
| Target Gene | Full name | Primer Sequences | Accession Number |
|---|---|---|---|
| Beta-actin | F: 5′-TGGACTCTGGTGATGGTGTGAC-3′ | AF057040.1 | |
| R: 5′-GAGGAAGAAGAGGCAGCGGTTC-3′ | |||
| Cu/Zn-superoxide dismutase | F: 5′-GTCGTCTGGCTTGTGGAGTG-3′ | Y12236 | |
| R: 5′-TGTCAGCGGGCTAGTGCTT-3′ | |||
| Catalase | F: 5′-AGGGCAACTGGGATCTTACA-3′ | AF170069 | |
| R: 5′-TTTATGGGACCAGACCTTGG-3′ | |||
| Glutathione peroxidase | F: 5′-AGATGTCATTCCTGCACACG-3′ | AW232474 | |
| R: 5′-AAGGAGAAGCTTCCTCAGCC-3′ | |||
| Apolipoprotein A-la | F: 5′-TGACAACCTGGACGGAACCGACTA-3′ | NM131128 | |
| R: 5′-GCTGCTTGGTGTTCTCCATCAACTG-3′ | |||
| Arachidonate 12-lipoxygenase | F: 5′-CGATCTTCACCAGCACAGCACAACA-3′ | NM199618 | |
| R: 5′-TGTCAGGCAGCGTGTCCATAATCAT-3′ | |||
| Arachidonate 5-lipoxygenase a | F: 5′-CGAGAGAGGAGCGGTGGACTCATAT-3′ | NM001256747 | |
| R: 5′-GTCATCAACCAACCAGCGGAAGCA-3′ | |||
| Succinate dehydrogenase complex assembly factor 2 | F: 5′-TGCTCCAGAACCGACCATCCTTGA-3′ | NM001082864 | |
| R: 5′-TGCGGCTCTCGTACAGCAGTCT-3′ | |||
| Glyceraldehyde-3-phosphate dehydrogenase | F: 5′-GACGCTGGTGCTGGTATTGCTCTC-3′ | NM001115114 | |
| R: 5′-CCATCAGGTCACATACACGGTTGCT-3′ | |||
| Lactate dehydrogenase A4 | F: 5′-TGCTCGTTTCCGCTACTTGATGGG-3′ | NM131246 | |
| R: 5′-ACGCTCTTCCAGTCCTCCTTGTCTT-3′ | |||
| HemK methyltransferase family member 1 | F: 5′-TGCGGTTGTTGTGCTGTGGTAGT-3′ | NM001114419 | |
| R: 5′-GATGCGGTGCAGGCTGAAGTGT-3′ | |||
| Catechol-O-methyltransferase a | F: 5′-TGTTGGCATCTGTCCTGGTACTCCT-3′ | NM001030157 | |
| R: 5′-CGCTGTGGTCGTGATAGTCCTGTG-3′ | |||
| Cytochrome P450, family 2, subfamily AA, polypeptide 4 | F: 5′-GCATCGTGGGTATAGTCCGCTATCC-3′ | NM001002092 | |
| R: 5′-CGCTCAACGGCTGTGCTGTTATTG-3′ | |||
| Cytochrome P450, family 2, subfamily K, polypeptide 6 | F: 5′-ACGCAGGGTTTGCATTGGAGAGAG-3′ | NM200509 | |
| R: 5′-CAGTTGGTGTGGCTTCGGATTCAGT-3′ | |||
| Cytochrome P450, family 19, subfamily A, polypeptide 1b | F: 5′-TCCGCTGTGTACCATGTCCTGAAGA-3′ | NM131642 | |
| R: 5′-CTGACTTCTGGAGACCTGGACCTGT-3′ |